| Display title | Chemistry:Darolutamide |
| Default sort key | Darolutamide |
| Page length (in bytes) | 39,110 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 555763 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>JTerm |
| Date of page creation | 23:01, 5 February 2024 |
| Latest editor | imported>JTerm |
| Date of latest edit | 23:01, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or... |
